Karina Bispo dos Santos

Ms. Karina Bispo dos Santos

Universidade Estadual de Campinas - UNICAMP
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell Metabolism
Verified
Journal Article
Closed access
ACAna Campos Codo
Ana Campos Codo
GDGustavo Gastão Davanzo
Gustavo Gastão Davanzo
LMLauar de Brito Monteiro
Lauar de Brito Monteiro
GSGabriela Fabiano de Souza
Gabriela Fabiano de Souza
SMStéfanie Primon Muraro
Stéfanie Primon Muraro
Pedro M Moraes-VieiraPedro M Moraes-Vieira
Pedro M Moraes-Vieira

31 July 2023 in eLife
Verified
Journal Article
Open access
NBNatália Brunetti
Natália Brunetti
GDGustavo G Davanzo
Gustavo G Davanzo
DMDiogo de Moraes
Diogo de Moraes
AFAllan Jr Ferrari
Allan Jr Ferrari
GSGabriela F Souza
Gabriela F Souza
AFAlessandro S Farias
Alessandro S Farias
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 infects mainly lungs and may cause several immune-related complications, such as lymphocytopenia and cytokine storm, which are associated with the severity of the disease and predict mortality. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is still not fully understood. Here, we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells. This leads to impaired CD4 T cell function and may cause cell death. SARS-CoV-2-infected T helper cells express higher levels of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may contribute to a poor immune response in COVID-19 patients.

1 January 2021 in Gut Microbes
Verified
Journal Article
Open access
Lívia Bitencourt PascoalLívia Bitencourt Pascoal
Lívia Bitencourt Pascoal
PRPatrícia Brito Rodrigues
Patrícia Brito Rodrigues
LGLívia Moreira Genaro
Lívia Moreira Genaro
AGArilson Bernardo dos Santos Pereira Gomes
Arilson Bernardo dos Santos Pereira Gomes
DTDaniel Augusto Toledo-Teixeira
Daniel Augusto Toledo-Teixeira
Raquel Franco LealRaquel Franco Leal
Raquel Franco Leal
Microbiota-derived molecules called short-chain fatty acids (SCFAs) play a key role in the maintenance of the intestinal barrier and regulation of immune response during infectious conditions. Recent reports indicate that SARS-CoV-2 infection changes microbiota and SCFAs production. However, the relevance of this effect is unknown. In this study, we used human intestinal biopsies and intestinal epithelial cells to investigate the impact of SCFAs in the infection by SARS-CoV-2. SCFAs did not change the entry or replication of SARS-CoV-2 in intestinal cells. These metabolites had no effect on intestinal cells’ permeability and presented only minor effects on the production of anti-viral and inflammatory mediators. Together our findings indicate that the changes in microbiota composition of patients with COVID-19 and, particularly, of SCFAs do not interfere with the SARS-CoV-2 infection in the intestine.

11 February 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
CLCaroline Sprengel Lima
Caroline Sprengel Lima
MMMelina Mottin
Melina Mottin
Leticia Ribeiro de AssisLeticia Ribeiro de Assis
Leticia Ribeiro de Assis
NMNathalya Cristina de Moraes Roso Mesquita
Nathalya Cristina de Moraes Roso Mesquita
BSBruna Katiele de Paula Sousa
Bruna Katiele de Paula Sousa
Luis RegasiniLuis Regasini
Luis Regasini

21 July 2020 in Viruses
Verified
Journal Article
Open access
PDF file
MAMariene Ribeiro Amorim
Mariene Ribeiro Amorim
MPMarjorie Pontelli
Marjorie Pontelli
GSGabriela De Souza
Gabriela De Souza
SMStefanie Muraro
Stefanie Muraro
DTDaniel A. Toledo-Teixeira
Daniel A. Toledo-Teixeira
José Luiz Proença-MódenaJosé Luiz Proença-Módena
José Luiz Proença-Módena
Oropouche orthobunyavirus (OROV) is an emerging arbovirus with a high potential of dissemination in America. Little is known about the role of peripheral blood mononuclear cells (PBMC) response during OROV infection in humans. Thus, to evaluate human leukocytes susceptibility, permissiveness and immune response during OROV infection, we applied RNA hybridization, qRT-PCR and cell-based assays to quantify viral antigens, genome, antigenome and gene expression in different cells. First, we observed OROV replication in human leukocytes lineages as THP-1 monocytes, Jeko-1 B cells and Jurkat T cells. Interestingly, cell viability and viral particle detection are maintained in these cells, even after successive passages. PBMCs from healthy donors were susceptible but the infection was not productive, since neither antigenome nor infectious particle was found in the supernatant of infected PBMCs. In fact, only viral antigens and small quantities of OROV genome were detected at 24 hpi in lymphocytes, monocytes and CD11c+ cells. Finally, activation of the Interferon (IFN) response was essential to restrict OROV replication in human PBMCs. Increased expression of type I/III IFNs, ISGs and inflammatory cytokines was detected in the first 24 hpi and viral replication was re-established after blocking IFNAR or treating cells with glucocorticoid. Thus, in short, our results show OROV is able to infect and remain in low titers in human T cells, monocytes, DCs and B cells as a consequence of an effective IFN response after infection, indicating the possibility of leukocytes serving as a trojan horse in specific microenvironments during immunosuppression.

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
William SouzaWilliam Souza
William Souza
MAMariene Ribeiro Amorim
Mariene Ribeiro Amorim
RCRenata Sesti Costa
Renata Sesti Costa
LCLais D. Coimbra
Lais D. Coimbra
DTDaniel A. Toledo-Teixeira
Daniel A. Toledo-Teixeira
José Luiz Proença-MódenaJosé Luiz Proença-Módena
José Luiz Proença-Módena
Background: A new SARS-CoV-2 lineage, named P.1 (20J/501Y.V3), has recently been detected in Brazil. Mutations accrued by the P.1 lineage include amino acid changes in the receptor-binding domain of the spike protein that also are reported in variants of concern in the United Kingdom (B.1.1.7) and South Africa (B.1.325). Methods: We isolated two P.1-containing specimens from nasopharyngeal and bronchoalveolar lavage samples of patients of Manaus, Brazil. We measured neutralization of the P.1 virus after incubation with the plasma of 19 COVID-19 convalescent blood donors and recipients of the chemically-inactivated CoronaVac vaccine and compared these results to neutralization of a SARS-CoV-2 B-lineage previously circulating in Brazil. Findings: The immune plasma of COVID-19 convalescent blood donors had 6-fold less neutralizing capacity against the P.1 than against the B-lineage. Moreover, five months after booster immunization with CoronaVac, plasma from vaccinated individuals failed to efficiently neutralize P.1 lineage isolates. Interpretation: These data indicate that the P.1 lineage may escape from neutralizing antibodies generated in response to polyclonal stimulation against previously circulating variants of SARS-CoV-2. Funding: São Paulo Research Foundation, MCTI/FINEP, Medical Research Council, National Council for Scientific and Technological Development, National Institutes of Health. Conflict of Interest: M.S.D. is a consultant for Inbios, Vir Biotechnology, NGMBiopharmaceuticals, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. Ethical Approval: All procedures followed the ethical standards of the responsible committee on humanexperimentation and approved by the ethics committees from the University of Campinas, Brazil (Approval number CONEP 4.021.484 for plasma collection of blood donors, CAEE32078620.4.0000.5404 and 30227920.9.0000.5404 for the sampling of vaccinated and viral genome sequencing, respectively). All patient data were anonymized before study inclusion.Informed consent was obtained from all subjects for being included in the study.